Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 220 antisense RNA 1 (TMEM220-AS1)
- Target
- TMEM220-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
Transmembrane protein 220 antisense RNA 1 (TMEM220-AS1) is a cytoplasmic long non-coding RNA that is endogenously expressed at low levels in hepatocellular carcinoma (HCC), where its downregulation correlates with poor prognosis and increased tumor invasiveness[1][2][3]. TMEM220-AS1 executes its tumor-suppressive function by transcriptionally enhancing the expression of TMEM220 (a membrane protein), inhibiting the Wnt/β-catenin signaling pathway, and acting as a competing endogenous RNA (ceRNA) that sponges oncogenic microRNAs, notably miR-484, to protect tumor-suppressive genes (e.g., MAGI1)[1][2][3]. Experimental overexpression of TMEM220-AS1 in tumor models limits proliferation, migration, invasion, EMT, and metastasis, with strong implications for its potential as a biomarker or therapeutic candidate in HCC[1][2][3].
- Other names
- TMEM220-AS1CTC-297N7.5
02
Biological functions
Tumor suppressionRegulation of cell proliferation, apoptosis, cell migration, and invasionNegative regulation of epithelial-mesenchymal transition (EMT)Positive regulation of TMEM220 expressionmiRNA sponge (especially for miR-484)
03
Disease associations
Cancer (notably hepatocellular carcinoma)
04
Biomarkers
TMEM220-AS1 low expression in tumors (prognostic biomarker for poor survival in HCC)TMEM220 expression (positively correlated with TMEM220-AS1, associated with survival)miR-484 (interaction with TMEM220-AS1, involved in malignancy)
Beyond the preview
Go deeper on Transmembrane protein 220 antisense RNA 1 (TMEM220-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transmembrane protein 220 antisense RNA 1 (TMEM220-AS1).